Healthscope Maintains Growth
Healthscope Managing Director, Bruce Dixon today announced a Net Profit, before Non Recurring Items for the last financial year of $74.9 million, an increase of 14% over the previous year.
Total Revenue of $1,488.7 million was a record and up16% over the previous year. EBITDA (Earnings before Interest, Tax, Depreciation and Amortisation) from continuing operations rose by 15%, to $197.9 million, cash flow from operations reached $124.2 million, an increase of 14%. Net profit, after Non Recurring Items (NRI) was $64.3 million.
This will result in a fully franked dividend of 10.0 cents per share or total dividends of 19.5 cents for the 2008 financial year, an increase of 11% on last year.
Mr Dixon said he was very pleased with the result. He said the main contributors to the company’s performance were strong revenue and margin improvement from core hospitals, the full year contribution of hospitals acquired during the previous financial year, solid domestic and international pathology revenue and acquisitions of the NMIG Medical Group and the New Zealand Diagnostics Group.
“In particular, Healthscope has recorded signienue growth and margin improvements in its hospitals and pathology areas. Particularly pleasing was the strong margin improvement in pathology in the second half.” he said.
The performance of the company in reducing lost time injuries for the year was particularly pleasing.
The company still had many growth options both domestically and offshore. A major brownfield expansion programme is well underway which will provide significant growth when completed.
The company will continue to review offshore opportunities as well as complementary hospital services domestically.
Thursday 21st August 2008